VOLITIONRX LTD. news, videos and press releases
For more news please use our advanced search feature.
VOLITIONRX LTD. - More news...
VOLITIONRX LTD. - More news...
- Volition Issues Business Review 2024
- VolitionRx Appoints LifeSci Advisors as Investor Relations Consultants
- Study shows Nu.Q® Lung Cancer Test differentiated malignant and benign nodules found by Low Dose CT screening
- VolitionRx Announces Pricing of up to $1.9 Million Registered Direct Offering
- VolitionRx Limited Announces Third Quarter 2024 Financial Results and Business Update
- VolitionRx Limited Schedules Third Quarter 2024 Earnings Conference Call and Business Update
- Volition Appoints Timothy I. Still as Chairman
- Volition to share new 'NETs in sepsis management' data insights at upcoming webinar
- Volition hosts NETs in sepsis management symposium at ESICM Lives 2024
- Volition Appoints Dr. Ethel Rubin as an Independent Director
- Volition Hosts KOL Roundtable on Sepsis
- VolitionRx Limited Announces Second Quarter 2024 Financial Results and Business Update
- VolitionRx Announces Pricing of up to $21.5 Million Registered Direct Offering
- VolitionRx Limited Schedules Second Quarter 2024 Earnings Conference Call and Business Update
- Volition appoints PharmaVentures for Capture PCR™ and oncology portfolio licensing
- VolitionRx Limited Issues Mid-Year Review Ahead of 2024 Annual Meeting
- Nexalin Technology and VolitionRX Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
- VolitionRx Limited to Present at Jefferies Global Healthcare Conference
- VolitionRx Limited Announces First Quarter 2024 Financial Results and Business Update
- VolitionRx Limited Schedules First Quarter 2024 Earnings Conference Call and Business Update
- Nu.Q® Vet Cancer Test launched in-clinic in U.S. and Europe through Antech
- VolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business Update
- VolitionRx Limited Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call and Business Update
- Volition and Fujifilm Vet Systems Launch Nu.Q® Vet Cancer Test in Japan
- Volition appoints Dr Andrew Retter as Chief Medical Officer
-
VolitionRx webinar: Unravelling the web of NETs in sepsis … Part II
- Volition to Share Nu.Q® NETs Strategy Update at Upcoming Webinar
- Volition Issues Business Review 2023
- VolitionRx Limited Announces Third Quarter 2023 Financial Results and Business Update
- VolitionRx Limited Schedules Third Quarter 2023 Earnings Conference Call and Business Update
